OWC Pharmaceutical Research Corp.

 

Dr. Stanley Hirsch – Chairman

Dr. Hirsch has extensive executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.

Dr. Hirsch served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd., since 2016, and has also Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc., since 2007.

Dr. Hirsch holds a D. Phil (1982) in Cell Biology and Immunolgy from Oxford University, UK. His educational experience also includes a B.Sc. degree with honors in Medical Biochemistry from the University of Capetown, South Africa (1979) among other academic honors and awards from Oxford University and University of Capetown 

 

Mr. Mordechai Bignitz – Chief Executive Officer (CEO)

motiMr. Bignitz has extensive experience in the management of investments and financial systems, accounting and taxation. Mr. Bignitz is involved in economic and financial consulting to companies in the field of technoogy. He is a seasoned financial manager, with over 30 years’ experience in investment management, specializing in all aspects of the planning and execution of deals at every level and much more. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and  as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER).

Mr. Bignitz is a CPA, holds a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.

 

Mr. Yossi Dagan, CPA (IL) – Chief Finance Officer (CFO)

Mr. Dagan’s experience with Nasdaq-listed companies in various industries provides financial, capital markets, accounting and regulatory expertise.

From 2015 to present, Mr. Dagan has served as CFO of Top Image Systems Ltd., a reporting company under the Securities Exchange Act of 1934, organized under the laws of Israel. TISA is a global company that employs 220 employees, principally in the US, Israel, Germany, UK, Singapore, Japan and Brazil. Mr. Dagan also served as VP of Finance at Kenshoo – an Israeli based global SaaS company employing 600 employees, as Corporate Controller at Imperva Inc. – a leading provider of cyber security solutions in the cloud and on premises that protect business-critical data and applications, and as a manager at PriceWaterhouseCoopers.

Mr. Dagan holds a CPA and a BA in Accounting and Business from The College of Management, Rishon Le’Zion, Israel.

 

Mr. Jeffrey Friedland – Advisory Board Member 

Mr. Jeffrey Friedland is an emerging market pioneer. Friedland Global Capital Pte Ltd. was one of the first American investment banks to establish a presence in China, and he can now be found on the forefront of the global cannabis industry as an investor as well as business owner.

In his book “Marijuana: The World’s Most Misunderstood Plant”, Mr. Friedland dives into the world of medical marijuana, discussing the plants history, what we know and what we still hope to discover. Mr. Friedland has been a frequent speaker at conferences and events, including speeches to individual and institutional investors on investments, emerging markets, and the global cannabis industry.

 

Ms. Miriam (Miri) Sani, MSc Eng. – Advisory Board Member

Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion – Israel Institute of Technology, Haifa, Israel, will advise OWC’s management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries. Ms. Sani will also supervise all manufacturing facilities of third party licensees to assure for quality control in accordance with OWC protocols that were developed at leading hospitals in Israel, for a steady and long-lasting quality of products and measured dosages.

Ms. Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OBYOGN and IVD’s through both regulatory affairs and clinical studies.

 

Dr. Sharon Rozenblat – Advisory Board Member

Dr. Rozenblat is tasked with overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company’s efforts to commercialize its cannabis-based formulations and delivery mechanisms.

Ms. Rozenblat earned her Ph.D. in biochemistry and cell biology (Magna Cum Laude) from Bar-Ilan University in Israel. Her research focused on botanical components for Melanoma (skin cancer) treatment. From 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.

Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in a joint venture with Green Mountain Biotech (GMB), in Chengdu, China, where she worked with GMB to find agricultural resources, develop extraction methods, establish quality control methodologies, and conduct safety and efficacy studies.

Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents.

 

 


 

One World Cannabis Ltd.

 

Mr. Mordechai Bignitz – Chief Executive Officer (CEO)

motiMr. Bignitz has extensive experience in the management of investments and financial systems, accounting and taxation. Mr. Bignitz is involved in economic and financial consulting to companies in the field of technoogy. He is a seasoned financial manager, with over 30 years’ experience in investment management, specializing in all aspects of the planning and execution of deals at every level and much more. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and  as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER).

Mr. Bignitz is a CPA, holds a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.

 

Mr. Alon Sinai – Chief Operating Officer (COO)

img_6330-273x300Mr. Sinai is a retired Lieutenant-Colonel from the Medical Corps of IDF (1987-2013), and completed the NATO School Oberammergau program (NATO’s premier individual training and education facility at the operational level). Most recently he served as Head of the Doctrine, Instruction and Training Department, where he was responsible for commanding and developing emergency medical facilities, writing professional doctrine and literature for the IDF Medical Corps and working with foreign militaries.

Mr. Sinai is currently pursuing his Ph.D. in Health Systems Management at Ben-Gurion University of the Negev, where he previously earned an MA in Health Systems Management and a B.EMS in Emergency Medicine.

 

Dr. Med. Yehuda Baruch – Director of Research and Regulatory Affairs 

img_63-255x300Dr. Baruch served as Head of the Israeli Ministry of Health’s Medical Marijuana Program from 2003 through 2013 where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. He has extensive experience in researching medical cannabis, most notably for its effect on PTSD.

From 2004 until recently he served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel. Prior to that, he was the director of Israel’s Ministry of Health medical management division, and director general of Be’er Yakov Mental Health Center. He has taught at Ben-Gurion University of the Negev and Tel Aviv University’s Sackler School of Medicine.

 

Mr. Yossi Dagan, CPA (IL) – Chief Finance Officer (CFO)

Mr. Dagan’s experience with Nasdaq-listed companies in various industries provides financial, capital markets, accounting and regulatory expertise.

From 2015 to present, Mr. Dagan has served as CFO of Top Image Systems Ltd., a reporting company under the Securities Exchange Act of 1934, organized under the laws of Israel. TISA is a global company that employs 220 employees, principally in the US, Israel, Germany, UK, Singapore, Japan and Brazil. Mr. Dagan also served as VP of Finance at Kenshoo – an Israeli based global SaaS company employing 600 employees, as Corporate Controller at Imperva Inc. – a leading provider of cyber security solutions in the cloud and on premises that protect business-critical data and applications, and as a manager at PriceWaterhouseCoopers.

Mr. Dagan holds a CPA and a BA in Accounting and Business from The College of Management, Rishon Le’Zion, Israel.